Forty-Second Board Meeting

Loading...
Date
YYYY-MM-DD
Board Meeting Decision Point Number Title
2019-11-14 B42 GF/B42/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
<p>Mary Isaac from the Latin American and Caribbean constituency is designated as Rapporteur for the 42nd Board Meeting</p>
2019-11-14 B42 GF/B42/DP02 Approval of the Agenda Approval of the Agenda
<p>The agenda for the 42nd Board Meeting (GF/B42/01-Revision 1) is approved.</p>
2019-11-14 B42 GF/B42/DP03 Sources and Uses of Funds for the 2020-2022 Allocation Period Sources and Uses of Funds for the 2020-2022 Allocation Period
<ol> <li>Based on the recommendation of the Audit and Finance Committee (the “AFC”), as presented in GF/B42/02, the Board decides the amount of sources of funds for allocation for the 2020-2022 allocation period is USD 13.00 billion, comprised of the following amounts, in accordance with the Comprehensive Funding Policy set forth in Annex 1 to GF/B36/02 – Revision 1 and approved through decision point GF/B36/DP04:<br /><br /> <ol type="i"> <li>USD 13.25 billion, derived from the announced replenishment results of the Sixth Replenishment (2020-2022), net of certain adjustments; and</li> <li>USD 0.65 billion of forecasted unutilized funds from the 2017-2019 allocation period;</li> <li>to which a reduction of USD 0.90 billion of forecasted aggregate operating expenses for the 2020-2022 allocation period is applied.<br /><br /></li> </ol> </li> <li>Based on the recommendation of the Secretariat, made in accordance with its delegated authority from the Board pursuant to decision point GF/B41/DP04, and after consultation with the Strategy Committee, the Board approves the use of an additional USD 0.09 billion for the 2020-2022 allocation period’s catalytic investments, bringing the total amount for catalytic investments for the 2020-2022 allocation period to USD 0.89 billion, to be made available for the priorities and associated costs set forth in Annex 1 of GF/B42/02.</li> <li>Additionally, based on the recommendation of the AFC and to help ensure the maximum amount of impact and use of funds over the 2020-2022 allocation period, the Board requests that the Secretariat include an additional USD 0.60 billion in the amount used to determine country allocations pursuant to the Allocation Methodology for the 2020-2022 Allocation Period as approved pursuant to GF/B41/DP03 (the “Allocation Methodology”).</li> <li>Accordingly, the Board decides the amount of sources of funds for country allocation for the 2020-2022 allocation period is USD 12.11 billion, to which USD 0.60 billion will be added prior to determining the country allocation, to be used in accordance with the Allocation Methodology and decision point GF/B41/DP03.</li> </ol>
2019-11-14 B42 GF/B42/DP04 2020 Work Plan and Budget Narrative and the 2020 Operating Expenses Budget 2020 Work Plan and Budget Narrative and the 2020 Operating Expenses Budget
<p>Based on the recommendation of the Audit and Finance Committee, the Board approves the following:</p> <ol> <li>2020 Work Plan and Budget Narrative, as set forth in GF/B42/03A; and</li> <li>the 2020 Operating Expenses Budget in the amount of US$ 305 million, as set forth in GF/B42/03B (the “2020 OPEX Budget”), which includes US$ 15.24 million for the Office of the Inspector General’s 2020 operating expenses.</li> </ol>
2019-11-14 B42 GF/B42/DP05 Evolving the wambo.org pilot for non-Global Fund-financed orders Evolving the wambo.org pilot for non-Global Fund-financed orders
<ol> <li>Based on the recommendation of the Strategy Committee as presented in GF/B42/04- Revision 1, the Board:<br /><br /> <ol type="i"> <li>reaffirms the importance of wambo.org and supports evolving the wambo.org pilot approved by the Board pursuant to GF/B37/DP09, as the number of transactions was increased pursuant to GF/SC09/DP01, to further its development and advancement;</li> <li>decides that, in connection with the evolution of the wambo.org pilot, wambo.org may be made available for non-Global Fund-financed orders by governments and non-government development organizations in Global Fund-eligible and transitioned countries, for all products, services and functionalities as they become available on wambo.org, subject, if applicable, to agreement by the product catalogue owners, as described in GF/B42/04- Revision 1, up to a cap of USD 50 million of transactions within the above scope from the date of this Decision Point; and</li> <li>instructs the Secretariat to undertake consultations early in 2020, an evaluation of the wambo.org pilot in 2022 and bi-annual reporting on progress of the wambo.org pilot to the Strategy Committee.<br /><br /></li> </ol> </li> <li>The Board delegates to the Strategy Committee the authority to: <ol type="i"> <li>approve a higher cap for transactions within the scope of Section 1(ii) above on a pilot basis prior to the consultations in 2020; and</li> <li>establish the future parameters of the wambo.org pilot within the scope of Section 1(ii) above, based on the outcome of the 2020 consultations.</li> </ol> </li> <li>The Board requests the Secretariat to include the results of the evaluation referred to in Section 1(iii) in the development of a strategy for future advancement of wambo.org to be presented for Board approval at the conclusion of the wambo.org pilot for non-Global Fund-financed orders no later than November 2022.</li> </ol>
2019-11-14 B42 GF/B42/DP06 Revisions to the selection process of the members of the Board Standing Committees and to the Charters of the Board Standing Committees Revisions to the selection process of the members of the Board Standing Committees and to the Charters of the Board Standing Committees
<p>The Board, cognizant of the overarching desire of fostering the further participation of constituencies across the Board Standing Committees, and mindful that the composition of the Board Standing Committees should reflect the broad partnership that brings together representatives from donor and implementer governments, communities, civil society, the private sector, the private foundations and the technical partners:</p> <ol> <li>Expresses its sincere appreciation for the comprehensive work done by the Ethics and Governance Committee (“EGC”) over the course of the last year in relation to the strengthening the process for the selection of committee members.</li> <li>Decides that the Board Leadership shall consider the principles set out below when submitting the list of proposed members for committee membership pursuant to article 43.3 of the Board and Committees Operating Procedures as of the next selection process of the members of the Board Standing Committees:<br /><br /> <ol type="i"> <li>Each voting constituency should be represented in the Strategy Committee (“SC”) and the Audit and Finance Committee (“AFC”) for at least one term within a three two-year terms cycle;</li> <li>Each voting constituency should be represented, in any given term, in at least, the SC or the AFC;</li> <li>For the above committees, the implementer group representation should include government and civil society/communities;</li> <li>Each voting constituency should have the opportunity to have an individual nominated by it serving in their personal capacity in the EGC within a three two-year terms cycle;</li> <li>In setting out the list of proposed members, the Board Leadership shall consider experience, competency, continuity and gender balance.<br /><br /></li> </ol> </li> <li>Decides to amend article 4 of the Charter of the EGC by deleting the words “according to a pre-established rotation of membership of constituencies”; the revised article 4 of the EGC Charter, as amended, shall therefore read as follows: “Nomination and appointment of Committee Members shall be according to the Operating Procedures of the Board and Committees”.</li> <li>Decides to amend article 3.a. the Charter of the SC and article 3.a. of the Charter of the AFC by, in each case, increasing the number of voting representatives of constituencies from the implementer group by one; the revised article 3.a. of the Charter of the SC and article 3.a. of the Charter of the AFC, as amended, shall therefore read as follows: “Six voting representatives of constituencies from the implementer group”.</li> <li>Decides to amend article 3.b. of the Charter of the SC and article 3.b. of the Charter of the AFC by increasing the number of voting representatives of constituencies from the donor group by one in each case; the revised article 3.b. of the Charter of the SC and article 3.b. of the Charter of the AFC, as amended, shall therefore read as follows: “Six voting representatives of constituencies from the donor group”.</li> <li>The amendments to the EGC Charter, the AFC Charter and the SC Charter set out in paragraphs 3 to 5 of this decision point shall enter into force upon the expiry of the term of the current EGC, the AFC and SC in May 2020.</li> </ol>
2019-12-23 B42 GF/B42/EDP01 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 1 of GF/B42/ER01 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>
2020-02-05 B42 GF/B42/EDP02 Approval of the Report of the Global Fund 42nd Board Meeting Approval of the Report of the Global Fund 42nd Board Meeting
<p>The Board approves the Report of the 42nd Board Meeting, as set forth in GF/B42/ER22.</p>
2020-02-14 B42 GF/B42/EDP03 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 1 of GF/B42/ER03 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2020-03-10 B42 GF/B42/EDP04 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 1 of GF/B42/ER04 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>
2020-03-12 B42 GF/B42/EDP05 Appointment of the Chairs and Vice-Chairs of the Standing Committees of the Board Appointment of the Chairs and Vice-Chairs of the Standing Committees of the Board
<ol> <li>The Board approves the appointment of: <ol type="i"> <li>Michael Ruffner as Chair of the Audit and Finance Committee;</li> <li>Edward Ouko as Vice-Chair of the Audit and Finance Committee;</li> <li>Suomi Sakai as Vice-Chair of the Ethics and Governance Committee;</li> <li>Rico Gustav as Chair of the Strategy Committee; and</li> <li>Gunilla Carlsson as Vice-Chair of the Strategy Committee.</li> </ol> </li> <li>The Board notes each Committee Chair and Vice-Chair appointed under this decision point shall begin their term on 16 May 2020 and serve for two years or until the appointment of their successor.</li> </ol>
2020-03-18 B42 GF/B42/EDP06 Appointment of a Replacement Member on the Strategy Committee Appointment of a Replacement Member on the Strategy Committee
<p>The Board approves the appointment of Ms Reem Ghanim Al-Sulaiti, representing the Additional Public Donors Constituency, as a non-voting member of the Strategy Committee for a term that will expire in May 2020, or until the appointment of her successor.</p>
2020-04-09 B42 GF/B42/EDP07 2019 Annual Financial Report 2019 Annual Financial Report
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2019 Annual Financial Report, including the 2019 Consolidated Financial Statements which have been audited by KPMG SA, as set forth in Annex 1 to GF/B42/ER07.</p>
2020-04-09 B42 GF/B42/EDP08 2019 Statutory Financial Statements 2019 Statutory Financial Statements
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2019 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in Annex 2 to GF/B42/ER07.</p>
2020-04-15 B42 GF/B42/EDP09 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 1 of GF/B42/ER08 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2020-04-09 B42 GF/B42/EDP10 Operational Flexibilities to Ensure Continued Operations during COVID-19 Operational Flexibilities to Ensure Continued Operations during COVID-19
<p>The Board acknowledges the severe negative impact COVID-19 is having on country health systems and Global Fund programs to fight the three diseases. The Board agrees with the need for temporary flexibilities to ensure the continued delivery of the Global Fund’s core mission during a prolonged period of disruption.</p> <p>Based on the recommendation of the Secretariat, as presented in GF/B42/ER09 – Revision 1, the Board approves the following:</p> <ol> <li>In order to account for delays in the supply chain due to COVID-19 disruptions, the Secretariat may allow additional flexibility for the deadline for delivery of goods and services under Global Fund programs to be funded from the 2017-2019 allocation period, up to a maximum of 180 days after the implementation period end date;</li> <li>In order to ensure swift deployment of portfolio optimization funds, the Secretariat may approve the increase of grant amounts to integrate awards of portfolio optimization funds approved by the Secretariat in line with the Strategy Committee-approved prioritization framework, where such funds have been approved as available by the AFC, with subsequent reporting to the Board; and</li> <li>In order to mitigate risks of disruption to the supply of health products in-country, the Secretariat may grant limited exceptions to the Quality Assurance Policies, to waive the requirement for pre-shipment sampling and testing for Expert Review Panel-approved products, vector control products, and condoms, where such testing may delay the delivery of products to countries.</li> </ol> <p>The Secretariat may apply the temporary flexibilities described in paragraphs 2 and 3 above for an initial six-month period, subject to renewal by the Board. The Secretariat may apply the flexibility described in paragraph 1 through 30 June 2021.</p>
2020-04-09 B42 GF/B42/EDP11 Additional Support for Country Responses to COVID-19 Additional Support for Country Responses to COVID-19
<p>The Board agrees that the COVID-19 pandemic poses a global public health emergency and that failure to control the pandemic threatens to derail the Global Fund’s mission to fight HIV/AIDS, tuberculosis, and malaria and strengthen systems for health. The Board acknowledges that without immediate action, health facilities, communities and geographies served by Global Fund programs will be severely impacted. As a major actor in global health, the Global Fund is uniquely positioned to deliver rapid support to countries developing responses to control the COVID-19 pandemic. In light of the urgency of the situation, and the need to take swift and decisive action with partners to control the impact of COVID-19 on the Global Fund mission and country health systems, the Board:</p> <ol> <li>Approves the creation of a temporary COVID-19 response mechanism (C19RM) to provide additional support for country responses to the pandemic and to ensure the continuity of the fight against HIV, tuberculosis, and malaria. C19RM will: <ol type="a"> <li>Support the rapid deployment of funds to support implementer countries’ COVID-19 responses, using expedited decision-making approaches determined by the Secretariat and coordinated with partners;</li> <li>Finance interventions consistent with World Health Organization (WHO) guidance on COVID-19 and national Strategic Preparedness and Response Plans, including: <ol type="i"> <li>COVID-19 control and containment interventions, including personal protective equipment, diagnostics, treatment, communications and other public measures as specified in WHO guidance;</li> <li>COVID-19-related risk mitigation measures for programs to fight HIV/AIDS, tuberculosis, and malaria; and</li> <li>Expanded reinforcement of key aspects of health systems, such as laboratory networks, supply chains, and community-led response systems, to address advocacy, services, accountability, and human-rights based approaches;</li> </ol> </li> <li>Finance interventions across the 5th and 6th replenishment periods;</li> <li>Be administered within the established internal control framework of the Global Fund; and</li> <li>Be additional to amounts approved by the Global Fund for programming towards COVID-19 interventions under existing grants.</li> </ol> </li> <li>Approves initial funding for C19RM of up to USD 500 million, comprised of: <ol type="a"> <li>USD 180 million from the USD 300 million of available funds approved by the Audit and Finance Committee on 16 March 2020 under GF/AFC12/DP01; and</li> <li>Up to USD 320 million of additional funds approved as available by the AFC under section E.6 of the Amended and Restated Comprehensive Funding Policy.</li> </ol> </li> <li>Agrees that C19RM funds may be used to procure COVID-19 products approved under the WHO Emergency Use and Listing procedures or under other emergency procedures set up by any Stringent Regulatory Authorities as defined under the Quality Assurance Policy for Pharmaceutical Products and Quality Assurance Policy for Diagnostic Products.</li> <li>Agrees that C19RM is a Board-approved initiative for which the Global Fund may mobilize additional resources from private and public donors, in accordance with existing policy.</li> <li>Agrees that the Secretariat may approve requests for C19RM funds for an initial six-month period through 30 September 2020, and that C19RM funds may be used through 30 June 2021. These dates may be extended by the Board, based on updated information on needs as the pandemic evolves.</li> <li>Requests the Secretariat to further operationalize the investment and management modalities for C19RM, including working with partners to deliver critical technical assistance, ensuring the appropriate involvement of Country Coordinating Mechanisms and alignment with the Global Fund’s underlying principles of gender equity and human rights, and providing the flexibility to take rapid action, including at global and regional level, in close collaboration with WHO and other critical partners, and provide regular reporting to the Board on the operationalization of C19RM, including on any investments made with C19RM funds.</li> </ol>
2020-05-11 B42 GF/B42/EDP13 Appointment of the Chair of the Ethics and Governance Committee (EGC) for the 2020-2022 term Appointment of the Chair of the Ethics and Governance Committee (EGC) for the 2020-2022 term
<ol> <li>The Board approves the appointment of Magda Robalo Correia e Silva as Chair of the Ethics and Governance Committee.</li> <li>The Board notes that the Chair of the Ethics and Governance Committee appointed under this decision point shall begin her term on 16 May 2020 and serve for two years or until the appointment of her successor.</li> </ol>
2020-05-11 B42 GF/B42/EDP14 Appointment of the Members of the Standing Committees of the Board Appointment of the Members of the Standing Committees of the Board
<p>1. The Board approves the appointment of the following individuals to serve as voting members of the Audit and Finance Committee, representing the Board constituency listed by their name:</p> <ol type="i"> <li>Arun Thangaraj, Canada, Switzerland and Australia;</li> <li>Maurine Murenga, Communities;</li> <li>Revanta Dharmarajah, Developed Country NGO;</li> <li>Sara Mohammed, Eastern Mediterranean Region;</li> <li>Malefia Dereje, Eastern and Southern Africa;</li> <li>Pasqualino Procacci, European Commission, Belgium, Italy, Portugal, Spain;</li> <li>Gilles Angles, France;</li> <li>Guillermo Birmingham, Latin America and the Caribbean;</li> <li>Greg Ferrante, Private Foundations;</li> <li>Sherwin Charles, Private Sector;</li> <li>Bharati Das, South East Asia; and</li> <li>Chris Taylor, United Kingdom.</li> </ol> <p>The Board appoints the following individuals to serve as non-voting members of the Audit and Finance Committee, representing the Board constituency listed by their name:</p> <ol start="13" type="i"> <li>Heesun Shin, Additional Public Donors; and</li> <li>Alexandru Chitic Patapievici, World Bank.</li> </ol> <p>2. The Board approves the appointment of the following individuals to serve in their personal capacity as voting members of the Ethics and Governance Committee:</p> <ol type="i"> <li>Alexander Schulze, Canada, Switzerland and Australia;</li> <li>Berry Nibogora, Developing Country NGO</li> <li>Mohamed Chakroun, Eastern Mediterranean Region;</li> <li>Rudolph Maziya, Eastern and Southern Africa;</li> <li>Anders Nordström, Point Seven;</li> <li>Renuka Gadde, Private Sector;</li> <li>Sandra Thurman, United States; and</li> <li>Pascal Niamba, West and Central Africa.</li> </ol> <p>3. The Board approves the appointment of the following individuals to serve as voting members of the Strategy Committee, representing the Board constituency listed by their name:</p> <ol type="i"> <li>J. Carolyn Gomes, Developing Country NGO;</li> <li>Nataliya Nizova, Eastern Europe and Central Asia;</li> <li>Nduku Kilonzo, Eastern and Southern Africa;</li> <li>Stéphanie Seydoux, France;</li> <li>Birgit Pickel, Germany;</li> <li>Naoki Akahane, Japan;</li> <li>Marja Esveld, Point Seven;</li> <li>Kieran Daly, Private Foundations;</li> <li>Suriya Wongkongkathep, South East Asia;</li> <li>Mamadi Yilla, United States</li> <li>Oumar Djalo Boukou, West and Central Africa; and</li> <li>Jim Tulloch, Western Pacific Region.</li> </ol> <p>Noting that the Chairs of the Technical Review Panel and the Technical Evaluation Reference Group serve as non-voting members of the Strategy Committee, the Board appoints the following individuals to serve as additional non-voting members of the Strategy Committee:</p> <ol start="13" type="i"> <li>Lucica Ditiu, Partners (Stop TB);</li> <li>Victor Bampoe, UNAIDS; and</li> <li>Mubashar Sheikh, World Health Organization.</li> </ol> <p>4. The Board notes each of the individuals appointed under this decision point shall begin his/her term on 16 May 2020 and serve for two years or until the appointment of his/her successor.</p>
2020-05-04 B42 GF/B42/EDP12 Approval of dates and format of the 6th Partnership Forums Approval of dates and format of the 6th Partnership Forums
<p>The Global Fund Board, on 4 May 2020, decided on initial dates and locations for the 6th Partnership Forums for the development of the next Global Fund Strategy and, due to the evolving nature of the COVID-19 pandemic, delegated authority to its Strategy Committee to approve subsequent changes to 6th Partnership Forum locations and dates. On 5 October 2020, at its 14th meeting, the Strategy Committee decided to hold virtual Partnership Forums on the following revised dates:</p> <ol type="i"> <li>Partnership Forum I, 9-11 February, 2021: Eastern Europe and Central Asia &amp; Latin America and the Caribbean;</li> <li>Partnership Forum II, 17-19 February, 2021: Africa and MENA I;</li> <li>Partnership Forum III, 3-5 March, 2021: East Asia Pacific, South West Asia and MENA II.</li> </ol>